Experimental data indicate that despite high expression of KIRs in NK cells and tumor tissues, KIR-targeted therapies have demonstrated poor efficacy with frequent treatment escape phenomena, suggesting that gene editing at KIR loci may not yield ideal therapeutic results [31]. The gene discussed is KIR3DL1; the disease is neoplasm.